scholarly journals GE-06 * PROGNOSTIC SIGNIFICANCE OF RELATIVE 1p19q CODELETION IN OLIGODENDROGLIAL TUMORS

2014 ◽  
Vol 16 (suppl 5) ◽  
pp. v97-v97
Author(s):  
M. Chamberlain
Keyword(s):  
Prognostic Significance ◽  
1P19q Codeletion ◽  
Oligodendroglial Tumors

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

2013 ◽  
Vol 31 (3) ◽  
pp. 344-350 ◽  
Author(s):  
Martin J. van den Bent ◽  
Alba A. Brandes ◽  
Martin J.B. Taphoorn ◽  
Johan M. Kros ◽  
Mathilde C.M. Kouwenhoven ◽  
...  
Keyword(s):  
Methylation Status ◽  
Prognostic Significance ◽  
Phase Iii ◽  
Anaplastic Oligodendroglioma ◽  
Newly Diagnosed ◽  
Oligodendroglial Tumors ◽  
Mutational Status ◽  
Long Term Follow Up

Purpose Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT). Patients and Methods Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis. Results A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance. Conclusion The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non–1p/19q-deleted tumors.

scholarly journals Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors

2019 ◽  
Vol 21 (9) ◽  
pp. 1164-1174 ◽  
Author(s):  
Hui Chen ◽  
Cheddhi Thomas ◽  
Felipe Andres Munoz ◽  
Sanda Alexandrescu ◽  
Craig M Horbinski ◽  
...  
Keyword(s):  
Overall Survival ◽  
In Situ Hybridization ◽  
Chromosomal Instability ◽  
Prognostic Significance ◽  
Progression Free Survival ◽  
Early Recurrence ◽  
Free Survival ◽  
Short Survival ◽  
Oligodendroglial Tumors

AbstractBackgroundChromosomal instability is associated with earlier progression in isocitrate dehydrogenase (IDH)–mutated astrocytomas. Here we evaluated the prognostic significance of polysomy in gliomas tested for 1p/19q status.MethodsWe analyzed 412 histologic oligodendroglial tumors with use of 1p/19q testing at 8 institutions from 1996 to 2013; fluorescence in situ hybridization (FISH) for 1p/19q was performed. Polysomy was defined as more than two 1q and 19p signals in cells. Tumors were divided into groups on the basis of their 1p/19q status and polysomy and were compared for progression-free survival (PFS) and overall survival (OS).ResultsIn our cohort, 333 tumors (81%) had 1p/19q loss; of these, 195 (59%) had concurrent polysomy and 138 (41%) lacked polysomy, 79 (19%) had 1p/19q maintenance; of these, 30 (38%) had concurrent polysomy and 49 (62%) lacked polysomy. In agreement with prior studies, the group with 1p/19q loss had significantly better PFS and OS than did the group with 1p/19q maintenance (P < 0.0001 each). Patients with 1p/19q loss and polysomy showed significantly shorter PFS survival than patients with 1p/19q codeletion only (P < 0.0001), but longer PFS and OS than patients with 1p/19q maintenance (P < 0.01 and P < 0.0001). There was no difference in survival between tumors with >30% polysomic cells and those with <30% polysomic cells. Polysomy had no prognostic significance on PFS or OS in patients with 1p/19q maintenance.ConclusionsThe presence of polysomy in oligodendroglial tumors with codeletion of 1p/19q predicts early recurrence and short survival in patients with 1p/19q codeleted tumors.

scholarly journals MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

2009 ◽  
Vol 27 (35) ◽  
pp. 5881-5886 ◽  
Author(s):  
Martin J. van den Bent ◽  
Hendrikus J. Dubbink ◽  
Marc Sanson ◽  
Cathleen R. van der Lee-Haarloo ◽  
Monika Hegi ◽  
...  
Keyword(s):  
Promoter Methylation ◽  
Prognostic Significance ◽  
Progression Free Survival ◽  
Extent Of Resection ◽  
Mgmt Promoter Methylation ◽  
Prognostic Effect ◽  
Chromosome 1P ◽  
Oligodendroglial Tumors ◽  
Mgmt Promoter ◽  
Pcv Chemotherapy

Purpose O6-methylguanine-methyltransferase (MGMT) promoter methylation has been shown to predict survival of patients with glioblastomas if temozolomide is added to radiotherapy (RT). It is unknown if MGMT promoter methylation is also predictive to outcome to RT followed by adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with anaplastic oligodendroglial tumors (AOT). Patients and Methods In the European Organisation for the Research and Treatment of Cancer study 26951, 368 patients with AOT were randomly assigned to either RT alone or to RT followed by adjuvant PCV. From 165 patients of this study, formalin-fixed, paraffin-embedded tumor tissue was available for MGMT promoter methylation analysis. This was investigated with methylation specific multiplex ligation-dependent probe amplification. Results In 152 cases, an MGMT result was obtained, in 121 (80%) cases MGMT promoter methylation was observed. Methylation strongly correlated with combined loss of chromosome 1p and 19q loss (P = .00043). In multivariate analysis, MGMT promoter methylation, 1p/19q codeletion, tumor necrosis, and extent of resection were independent prognostic factors. The prognostic significance of MGMT promoter methylation was equally strong in the RT arm and the RT/PCV arm for both progression-free survival and overall survival. In tumors diagnosed at central pathology review as glioblastoma, no prognostic effect of MGMT promoter methylation was observed. Conclusion In this study, on patients with AOT MGMT promoter methylation was of prognostic significance and did not have predictive significance for outcome to adjuvant PCV chemotherapy. The biologic effect of MGMT promoter methylation or pathogenetic features associated with MGMT promoter methylation may be different for AOT compared with glioblastoma.

Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors

2012 ◽  
Vol 116 (6) ◽  
pp. 1172-1181 ◽  
Author(s):  
Tejas Sankar ◽  
Nina Z. Moore ◽  
Joshua Johnson ◽  
Lynn S. Ashby ◽  
Adrienne C. Scheck ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Contrast Enhancement ◽  
Tumor Tissue ◽  
Histological Grade ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Oligodendroglial Tumors ◽  
Blinded Observer ◽  
Volumetric Assessment ◽  
Time To Relapse

Object Oligodendrogliomas that enhance on MR images are associated with poor prognosis. However, the importance of the volume of enhancing tumor tissue, and the extent of its resection, is uncertain. The authors examined the prognostic significance of preoperative and residual postoperative enhancing tissue volumes in a large single-center series of patients with oligodendroglioma. They also examined the relationship between enhancement and characteristic genetic signatures in oligodendroglial tumors, specifically deletion of 1p and 19q (del 1p/19q). Methods The authors retrospectively analyzed 100 consecutive cases of oligodendroglioma involving patients who had undergone T1-weighted gadolinium-enhanced MRI at diagnosis and immediately after initial surgical intervention. The presence of preoperative enhancement was determined by consensus. Preoperative and residual postoperative volumes were measured using a quantitative, semiautomated method by a single blinded observer. Intrarater reliability for preoperative volumes was confirmed by remeasurement in a subset of patients 3 months later. Intrarater and interrater reliability for residual postoperative volumes was confirmed by remeasurement of these volumes by both the original and a second blinded observer. Multivariate analysis was used to assess the influence of contrast enhancement at diagnosis and the volume of pre- and postoperative contrast-enhancing tumor tissue on time to relapse (TTR) and overall survival (OS), while controlling for confounding clinical, pathological, and genetic factors. Results Sixty-three of 100 patients had enhancing tumors at initial presentation. Presence of contrast enhancement at diagnosis was related to reduced TTR and OS on univariate analysis but was not significantly related on multivariate analysis. In enhancing tumors, however, greater initial volume of enhancing tissue correlated with shortened TTR (p = 0.00070). Reduced postoperative residual enhancing volume and a relatively greater resection of enhancing tissue correlated with longer OS (p = 0.0012 and 0.0041, respectively). Interestingly, patients in whom 100% of enhancing tumor was resected had significantly longer TTR (174 vs 64 weeks) and OS (392 vs 135 weeks) than those with any residual enhancing tumor postoperatively. This prognostic benefit was not consistently maintained with greater than 90% or even greater than 95% resection of enhancing tissue. There was no relationship between presence or volume of enhancement and del 1p/19q. Conclusions In enhancing oligodendrogliomas, completely resecting enhancing tissue independently improves outcome, irrespective of histological grade or genetic status. This finding supports aggressive resection and may impact treatment planning for patients with these tumors.

scholarly journals Overexpression of PSAT1 Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with IDH1 Mutations and Chromosome 1p19q Codeletion

Cancers ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 13 ◽  
Author(s):  
Shang-Pen Huang ◽  
Yung-Chieh Chan ◽  
Shang-Yu Huang ◽  
Yuan-Feng Lin
Keyword(s):  
Gene Expression ◽  
Prognostic Marker ◽  
Cancer Metabolism ◽  
Prognostic Significance ◽  
Favorable Outcome ◽  
Lower Grade ◽  
1P19q Codeletion ◽  
Potential Biomarker ◽  
Idh1 Mutations ◽  
Genome Atlas

Patients with lower-grade gliomas (LGGs) have highly diverse clinical outcomes. Although histological features and molecular markers have been used to predict prognosis, the identification of new biomarkers for the accurate prediction of patient outcomes is still needed. The serine synthesis pathway (SSP) is important in cancer metabolism. There are three key regulators, including phosphoglycerate dehydrogenase (PHGDH), phosphoserine phosphatase (PSPH), and phosphoserine aminotransferase 1 (PSAT1), in SSP. However, their clinical importance in LGGs is still unknown. In this study, we used the bioinformatics tool in the Gene Expression Profiling Interactive Analysis (GEPIA) website to examine the prognostic significance of PHGDH, PSPH, and PSAT1 genes in LGGs. PSAT1 gene expression was then identified as a potential biomarker candidate for LGGs. Datasets from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) were further used to explore the prognostic role of PSAT1 gene. Our results demonstrated that PSAT1 overexpression is a favorable prognostic marker of LGGs and significantly correlated with patient age ≤40, and a lower WHO histological grade, as well as mutations in IDH1, TP53 and ATRX, but not with chromosome 1p19q codeletions. More importantly, LGG patients with isocitrate dehydrogenase 1 (IDH1) mutations, chromosome 1p19q codeletions, and PSAT1 overexpression may have the best overall survival (five-year survival rate: 100%). Finally, we observed a coordinated biological reaction between IDH1 mutations and PSAT1 overexpression, and suggested overexpression of PSAT1 might enhance the function of mutant IDH1 to promote a favorable outcome in LGG patients. In conclusion, our study confirmed the importance of identifying the overexpression of PSAT1 as a favorable prognostic marker of LGGs, which may compensate for the limitation of IDH1 mutations and chromosome 1p19q codeletion in the prognostication of LGGs.

Prognostic significance of MIB-1 labeling indices for oligodendroglial tumors

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 1533-1533 ◽  
Author(s):  
U. Abacioglu ◽  
M. Sengoz ◽  
E. Tezcanli ◽  
S. Akpulat ◽  
S. Peker ◽  
...  
Keyword(s):  
Prognostic Significance ◽  
Oligodendroglial Tumors ◽  
Mib 1

scholarly journals Promoter Hypermethylation of theEMP3Gene in a Series of 229 Human Gliomas

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Marta Mellai ◽  
Angela Piazzi ◽  
Valentina Caldera ◽  
Laura Annovazzi ◽  
Oriana Monzeglio ◽  
...  
Keyword(s):  
Protein Level ◽  
Prognostic Significance ◽  
Promoter Hypermethylation ◽  
Suppressor Gene ◽  
Low Grade ◽  
Human Gliomas ◽  
Oligodendroglial Tumors ◽  
Specific Pcr ◽  
Candidate Tumor Suppressor Gene ◽  
Oligodendroglial Component

The epithelial membrane protein 3 (EMP3) is a candidate tumor suppressor gene in the critical region 19q13.3 for several solid tumors, including tumors of the nervous systems. The aim of this study was to investigate theEMP3promoter hypermethylation status in a series of 229 astrocytic and oligodendroglial tumors and in 16 GBM cell lines. The analysis was performed by methylation-specific PCR and capillary electrophoresis. Furthermore, the EMP3 expression at protein level was evaluated by immunohistochemistry and Western blotting analysis. Associations ofEMP3hypermethylation with total 1p/19q codeletion,MGMTpromoter hypermethylation,IDH1/IDH2andTP53mutations, andEGFRamplification were studied, as well as its prognostic significance. TheEMP3promoter hypermethylation has been found in 39.5% of gliomas. It prevailed in low-grade tumors, especially in gliomas with an oligodendroglial component, and in sGBMs upon pGBMs. In oligodendroglial tumors, it was strongly associated with bothIDH1/IDH2mutations and total 1p/19q codeletion and inversely withEGFRgene amplification. No association was found withMGMThypermethylation andTP53mutations. In the whole series, theEMP3hypermethylation status correlated with 19q13.3 loss and lack of EMP3 expression at protein level. A favorable prognostic significance on overall survival of theEMP3promoter hypermethylation was found in patients with oligodendroglial tumors.

Ultrastructural features of prognostic significance in human oral cancer

1992 ◽  
Vol 50 (1) ◽  
pp. 618-619
Author(s):  
Karvita B. Ahluwalia ◽  
Nidhi Sharma
Keyword(s):  
Oral Cancer ◽  
Squamous Cell ◽  
Common Knowledge ◽  
Prognostic Significance ◽  
Growth Control ◽  
Terminal Differentiation ◽  
Squamous Cell Carcinomas ◽  
Effective Therapy ◽  
Invasive Potential ◽  
Biological Behaviour

It is common knowledge that apparently similar tumors often show different responses to therapy. This experience has generated the idea that histologically similar tumors could have biologically distinct behaviour. The development of effective therapy therefore, has the explicit challenge of understanding biological behaviour of a tumor. The question is which parameters in a tumor could relate to its biological behaviour ? It is now recognised that the development of malignancy requires an alteration in the program of terminal differentiation in addition to aberrant growth control. In this study therefore, ultrastructural markers that relate to defective terminal differentiation and possibly invasive potential of cells have been identified in human oral leukoplakias, erythroleukoplakias and squamous cell carcinomas of the tongue.

Sign in / Sign up

Export Citation Format

Share Document